Evidence map›Paper›PMID 30880960›Full record

ArticleInternational journal of nanomedicine2019

Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy.

Jian-Guo Sun, Qin Jiang, Xiao-Pei Zhang, Kun Shan, Bai-Hui Liu, Chen Zhao, Biao Yan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 82 citations in OpenAlex.

  1. Potential of Nanoparticle-Based Phototherapies for Future Treatment of Uveal Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jian-Guo SunEye Institute, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China, biao.yan@fdeent.org.
Qin JiangThe Affiliated Eye Hospital, Nanjing Medical University, Nanjing, China.
Xiao-Pei ZhangThe Affiliated Eye Hospital, Nanjing Medical University, Nanjing, China.
Kun ShanEye Institute, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China, biao.yan@fdeent.org.
Bai-Hui LiuDepartment of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai, China.
Chen ZhaoEye Institute, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China, biao.yan@fdeent.org.
Biao YanEye Institute, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China, biao.yan@fdeent.org.
Shanghai Medical College of Fudan University · CNNanjing Medical University · CNChildren's Hospital of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAntiangiogenic drugs usually have short-acting efficacy and poor treatment compliance. The purpose of this study was to determine whether mesoporous silica nanoparticles (MSNs) could be utilized as a nanodrug delivery system for improving antiangiogenic therapy. MATERIALS AND

methodsMSN-encapsulated bevacizumab nanoparticles were prepared by the nanocasting strategy and characterized by Fourier transform infrared, transmission electron microscopy, and Brunauer-Emmett-Teller method. Encapsulation efficiency and drug loading efficiency of MSN-encapsulated bevacizumab nanoparticles were calculated. The pharmacokinetics, cytotoxicity, and tissue toxicity were evaluated in vitro and in vivo. The antiangiogenic effects of MSN-bevacizumab nanoparticles were evaluated in vitro and in vivo.

resultsMSN encapsulation could prolong the residency of bevacizumab in vitreous/aqueous humor and maintain the long-lasting drug concentration. MSN-encapsulated bevacizumab nanoparticles did not show any obvious cytotoxicity and tissue toxicity. MSN-encapsulated bevacizumab nanoparticles were more effective than bevacizumab in suppressing vascular endothelial growth factor-induced endothelial cell proliferation, migration, and tube formation in vitro. MSN-encapsulated bevacizumab nanoparticles showed sustained inhibitory effects on corneal neovascularization and retinal neovascularization in vivo.

conclusionThis study provides a novel strategy of encapsulating bevacizumab to protect and deliver it, which could increase the time between administration and formulation shelf-life. MSN-encapsulated bevacizumab is a promising drug delivery alternative of antiangiogenic therapy.

Indexed as

Drug Delivery SystemsAngiogenesis InhibitorsAnimalsBevacizumabCell MovementCell ProliferationCorneal NeovascularizationDrug CarriersHumansHuman Umbilical Vein Endothelial CellsMaleMiceMice, Inbred C57BLNanoparticlesPorositySilicon DioxideAngiogenesis InhibitorsBevacizumabDrug CarriersSilicon Dioxideantiangiogenic therapybevacizumabmesoporous silica nanoparticleocular angiogenesis

Identifiers

PMID30880960
PMCPMC6396882
OpenAlexW2918082160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.